## GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2003

## SENATE BILL 897 RATIFIED BILL

AN ACT TO EXEMPT FROM PRIOR AUTHORIZATION REQUIREMENTS FOR PRESCRIPTION DRUGS UNDER THE MEDICAID PROGRAM ANTIHEMOPHILIC DRUGS PRESCRIBED FOR THE TREATMENT OF HEMOPHILIA AND BLOOD DISORDERS.				
REMOTRILIA AND BLOOD DISORDERS.				
The General Assembly of North Carolina enacts:				
The Conclusive Section Curonia chaets.				
<b>SECTION 1.</b> Part 6 of Article 2 of Chapter 108A of the General Statutes is				
amended by adding the following new section to read:				
amended by adding the following new section to read.				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.  Prior authorization shall not be required or utilized for any antihemophilic factor				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.  Prior authorization shall not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not be required for the treatment of hemophilia and blood disorders where the prescribed for the treatment of the prescribed for the prescribed for the treatment of the prescribed for the prescribed for the prescribed for the treatment of the prescribed for the prescrib				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.  Prior authorization shall not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not generically equivalent drug available. Nothing in this section shall prohibit the Secretary				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.  Prior authorization shall not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not generically equivalent drug available. Nothing in this section shall prohibit the Secretary from implementing a disease management program."				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.  Prior authorization shall not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not generically equivalent drug available. Nothing in this section shall prohibit the Secretary from implementing a disease management program."  SECTION 2. This act is effective when it becomes law and expires July 1 2006.				
"§ 108A-68.1. Certain prescription drugs exempt from prior authorization requirements.  Prior authorization shall not be required or utilized for any antihemophilic factor drugs prescribed for the treatment of hemophilia and blood disorders where there is not generically equivalent drug available. Nothing in this section shall prohibit the Secretary from implementing a disease management program."  SECTION 2. This act is effective when it becomes law and expires July 1				

2003.

		Beverly E. Perdue President of the Senate	
		Richard T. Morgan Speaker of the House of Re	epresentatives
		Michael F. Easley Governor	
Approved	m. this	day of	, 2003